MX389320B - Anticuerpos anti-tnfrsf25 - Google Patents
Anticuerpos anti-tnfrsf25Info
- Publication number
- MX389320B MX389320B MX2018014716A MX2018014716A MX389320B MX 389320 B MX389320 B MX 389320B MX 2018014716 A MX2018014716 A MX 2018014716A MX 2018014716 A MX2018014716 A MX 2018014716A MX 389320 B MX389320 B MX 389320B
- Authority
- MX
- Mexico
- Prior art keywords
- antibodies
- tnfrsf25
- tnfrsf25 antibodies
- epitope
- bind
- Prior art date
Links
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Developmental Biology & Embryology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662348009P | 2016-06-09 | 2016-06-09 | |
| PCT/US2017/036817 WO2017214547A1 (en) | 2016-06-09 | 2017-06-09 | Anti-tnfrsf25 antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018014716A MX2018014716A (es) | 2019-03-11 |
| MX389320B true MX389320B (es) | 2025-03-20 |
Family
ID=59078259
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018014716A MX389320B (es) | 2016-06-09 | 2017-06-09 | Anticuerpos anti-tnfrsf25 |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US10005843B2 (OSRAM) |
| EP (1) | EP3468998B1 (OSRAM) |
| JP (1) | JP6961625B2 (OSRAM) |
| KR (1) | KR102423942B1 (OSRAM) |
| CN (1) | CN109219620B (OSRAM) |
| AU (1) | AU2017278192A1 (OSRAM) |
| BR (1) | BR112018075222A2 (OSRAM) |
| CA (1) | CA3026652A1 (OSRAM) |
| DK (1) | DK3468998T3 (OSRAM) |
| IL (1) | IL263406B2 (OSRAM) |
| MX (1) | MX389320B (OSRAM) |
| RU (1) | RU2746314C2 (OSRAM) |
| SG (1) | SG11201810853UA (OSRAM) |
| WO (1) | WO2017214547A1 (OSRAM) |
| ZA (1) | ZA201808317B (OSRAM) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112014007426B1 (pt) | 2011-09-30 | 2023-01-03 | Teva Pharmaceuticals Australia Pty Ltd | Anticorpos contra tl1a e seus usos |
| SG11201705844SA (en) * | 2015-02-06 | 2017-08-30 | Heat Biologics Inc | Vector co-expressing vaccine and costimulatory molecules |
| TWI703158B (zh) | 2015-09-18 | 2020-09-01 | 美商希佛隆公司 | 特異性結合tl1a之抗體 |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| EP4021494A1 (en) * | 2019-08-30 | 2022-07-06 | Pelican Therapeutics, Inc. | Methods of treating cancer using tnfrsf25 antibodies |
| WO2021062371A1 (en) * | 2019-09-26 | 2021-04-01 | Pelican Therapeutics, Inc. | Tnfrsf25-mediated treatments of immune diseases and disorders |
| WO2022212668A1 (en) * | 2021-03-31 | 2022-10-06 | Heat Biologics, Inc. | Methods and compositions related to tnfrsf25/dr3 agonists |
| CN119256009A (zh) * | 2022-06-17 | 2025-01-03 | 塞莱克辛有限公司 | 与人dr3特异性结合的抗体及其用途 |
| CN120399074A (zh) * | 2023-06-02 | 2025-08-01 | 安徽金百奥生物科技有限公司 | 一种与人dr3胞外域高亲和力的纳米抗体 |
| GB202315963D0 (en) | 2023-10-18 | 2023-11-29 | Cancer Research Tech Ltd | Binding molecules |
| US12319742B1 (en) * | 2024-01-24 | 2025-06-03 | Shattuck Labs, Inc. | Antibodies that bind TNFRSF25 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| US5618920A (en) | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DK0531472T3 (da) | 1991-03-06 | 2003-12-01 | Merck Patent Gmbh | Humaniserede monoklonale antistoffer |
| AU669124B2 (en) | 1991-09-18 | 1996-05-30 | Kyowa Hakko Kirin Co., Ltd. | Process for producing humanized chimera antibody |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| GB9125979D0 (en) | 1991-12-06 | 1992-02-05 | Wellcome Found | Antibody |
| ZA931148B (en) | 1992-02-19 | 1993-08-18 | Schering Corp | Cloning and expression of humanized monoclonal antibodies against human interfluekin-4. |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US5705154A (en) | 1995-03-08 | 1998-01-06 | Schering Corporation | Humanized monoclonal antibodies against human interleukin-4 |
| CA2536086C (en) | 2003-08-20 | 2013-03-19 | University Of Miami | Inhibition of dr3 in the treatment of allergic lung inflammation |
| US7612179B2 (en) | 2003-11-28 | 2009-11-03 | Astrazeneca Ab | antibodies binding to a C-terminal fragment of apoliopoprotein E |
| CA2621083C (en) | 2005-08-30 | 2017-04-11 | University Of Miami | Immunomodulating tumor necrosis factor receptor 25 (tnfr25) agonists, antagonists and immunotoxins |
| SG178712A1 (en) | 2006-10-02 | 2012-03-29 | Medarex Inc | Human antibodies that bind cxcr4 and uses thereof |
| FR2907341B1 (fr) | 2006-10-18 | 2012-08-17 | Pf Medicament | Utilisation d'un anticorps anti-cd151 pour le traitement du cancer |
| WO2010033913A1 (en) | 2008-09-22 | 2010-03-25 | Icb International, Inc. | Antibodies, analogs and uses thereof |
| JP2013501057A (ja) | 2009-08-03 | 2013-01-10 | ユニバーシティー・オブ・マイアミ | 制御性ｔ細胞のｉｎｖｉｖｏにおける増殖 |
| WO2011106707A2 (en) * | 2010-02-26 | 2011-09-01 | Human Genome Sciences, Inc. | Antibodies that specifically bind to dr3 |
| GB201020995D0 (en) | 2010-12-10 | 2011-01-26 | Bioinvent Int Ab | Biological materials and uses thereof |
| JP2013040160A (ja) | 2011-07-01 | 2013-02-28 | Genentech Inc | 自己免疫疾患を治療するための抗ｃｄ８３アゴニスト抗体の使用 |
| US20140193410A1 (en) | 2013-01-09 | 2014-07-10 | University Of Miami | Compositions and Methods for the Regulation of T Regulatory Cells Using TL1A-Ig Fusion Protein |
| RU2551235C2 (ru) * | 2013-08-26 | 2015-05-20 | Илья Владимирович Духовлинов | Гуманизированное моноклональное антитело, специфичное к синдекану-1 |
| CN103592439B (zh) * | 2013-09-03 | 2015-10-21 | 天津亿美诺生物科技有限公司 | 人尿路上皮癌特异性抗体及其应用 |
| US9982057B2 (en) * | 2014-11-17 | 2018-05-29 | Pelican Therapeutics, Inc. | Human TNFRSF25 antibody |
-
2017
- 2017-06-09 CN CN201780034593.5A patent/CN109219620B/zh not_active Expired - Fee Related
- 2017-06-09 RU RU2018143977A patent/RU2746314C2/ru active
- 2017-06-09 JP JP2018563618A patent/JP6961625B2/ja not_active Expired - Fee Related
- 2017-06-09 MX MX2018014716A patent/MX389320B/es unknown
- 2017-06-09 AU AU2017278192A patent/AU2017278192A1/en not_active Abandoned
- 2017-06-09 US US15/618,993 patent/US10005843B2/en active Active
- 2017-06-09 WO PCT/US2017/036817 patent/WO2017214547A1/en not_active Ceased
- 2017-06-09 CA CA3026652A patent/CA3026652A1/en active Pending
- 2017-06-09 SG SG11201810853UA patent/SG11201810853UA/en unknown
- 2017-06-09 BR BR112018075222-3A patent/BR112018075222A2/pt not_active IP Right Cessation
- 2017-06-09 EP EP17731434.1A patent/EP3468998B1/en active Active
- 2017-06-09 DK DK17731434.1T patent/DK3468998T3/da active
- 2017-06-09 KR KR1020187035804A patent/KR102423942B1/ko active Active
- 2017-06-09 IL IL263406A patent/IL263406B2/en unknown
-
2018
- 2018-04-27 US US15/964,775 patent/US10683359B2/en not_active Expired - Fee Related
- 2018-12-10 ZA ZA2018/08317A patent/ZA201808317B/en unknown
-
2020
- 2020-05-14 US US16/874,290 patent/US20210017287A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| RU2746314C2 (ru) | 2021-04-12 |
| IL263406B1 (en) | 2023-05-01 |
| RU2018143977A (ru) | 2020-07-09 |
| WO2017214547A1 (en) | 2017-12-14 |
| DK3468998T3 (en) | 2022-03-07 |
| CN109219620B (zh) | 2023-01-31 |
| KR20190015716A (ko) | 2019-02-14 |
| US20210017287A1 (en) | 2021-01-21 |
| JP6961625B2 (ja) | 2021-11-10 |
| US10683359B2 (en) | 2020-06-16 |
| MX2018014716A (es) | 2019-03-11 |
| AU2017278192A1 (en) | 2018-12-13 |
| RU2018143977A3 (OSRAM) | 2020-10-05 |
| KR102423942B1 (ko) | 2022-07-22 |
| IL263406A (en) | 2018-12-31 |
| CA3026652A1 (en) | 2017-12-14 |
| IL263406B2 (en) | 2023-09-01 |
| EP3468998B1 (en) | 2021-12-01 |
| US20180312599A1 (en) | 2018-11-01 |
| SG11201810853UA (en) | 2019-01-30 |
| EP3468998A1 (en) | 2019-04-17 |
| JP2019526528A (ja) | 2019-09-19 |
| ZA201808317B (en) | 2019-08-28 |
| CN109219620A (zh) | 2019-01-15 |
| US20170355773A1 (en) | 2017-12-14 |
| BR112018075222A2 (pt) | 2019-03-19 |
| US10005843B2 (en) | 2018-06-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX389320B (es) | Anticuerpos anti-tnfrsf25 | |
| CY1123163T1 (el) | Αντισωματα που δεσμευουν beta klotho επικρατεια 2 και μεθοδοι χρησης αυτων | |
| CY1125241T1 (el) | Υποδορια σκευασματα αντισωματων anti-cd38 και οι χρησεις τους | |
| CY1123977T1 (el) | Anti-pd-1 και anti-lag3 αντισωματα για την θεραπεια του καρκινου | |
| EA201791485A1 (ru) | Анти-cd47-антитела и их применения | |
| PH12019501405A1 (en) | Anti-neuropilin antigen-binding proteins and methods of use thereof | |
| EA201892386A1 (ru) | Химерные нейротоксины | |
| PH12017502390A1 (en) | Constructs targeting ny-eso-1 peptide/mhc complexes and uses thereof | |
| EA201890285A1 (ru) | Антитела против pd-1, активируемые антитела против pd-1 и способы их применения | |
| EA201892294A1 (ru) | Антитела и композиции против tim-3 | |
| EA201790334A1 (ru) | Конъюгаты анти-cdh6 антитела с лекарственным средством | |
| EA201791093A1 (ru) | Антитела к cd47, способы и применение | |
| JOP20190055A1 (ar) | أجسام مضادة ضد cd27 | |
| BR112016023948A2 (pt) | proteínas fc multiméricas | |
| JO3664B1 (ar) | أجسام مضادة لـ tigit | |
| JOP20190093A1 (ar) | أجسام مضادة لـ il-33 واستخداماتها | |
| TR201908550T4 (tr) | Profilaktik veya terapötik uygulamalar için lipozomal sferik nükleik asitler tarafından immün modülatörlerin çok değerlikli teslimi. | |
| JOP20160131B1 (ar) | الأجسام المضادة للعامل xi وطرق الاستخدام | |
| EA201690314A1 (ru) | Анти-garp-белок и его применения | |
| BR112016018891A2 (pt) | anticorpos anti-dll3 e conjugados de fármacos para uso em melanoma | |
| UY36021A (es) | Proteìnas fc multimèricas | |
| EA201692539A1 (ru) | Антитела и антигенсвязывающие фрагменты, которые специфично связываются с белком тау, ассоциированным с микротрубочками | |
| UY37456A (es) | Inmunoglobulinas y sus usos | |
| EA201890747A1 (ru) | Способы лечения воспалительных заболеваний | |
| EP3518971A4 (en) | Antibody and protein therapeutic formulations and uses thereof |